McGill University today announced it has signed agreements with ModernaTX, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to support two innovative research projects in the area of lipid nanoparticles (LNPs). LNPs are critical components in mRNA medicines such as vaccines, as they are the primary delivery method of mRNA strands to the target cells.
Read MoreA CRO, or contract research organization, is a company that provides, on a contractual basis, services in the biomedical research field. Given their crucial role in the development of new treatments and technologies, as well as their economic importance, BIOQuébec and CATALIS, with financial support from the Ministry of Economy and Innovation, conducted a study of Quebec CROs to chart the sector’s impact and measure its growth, strengths, and needs.
Read MoreDiex Research announces the official opening of its Quebec City site since its relocation on September 12, 2022, which is now located at Place de la Cité. Diex Research is a leader in the clinical research industry and is committed to providing superior services to its clients while maintaining the highest standards for safety and ethics.
Read MoreAplantex is pleased to announce the composition of the company’s C-suite. "Aplantex is the result of the innovative work of a multidisciplinary team of skilled individuals committed to simplifying and broadening access to the valuable plant-based bioactive molecules that daily impact our health and well-being," states Mr. Charest.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces that the first patient has been dosed with DT-9081, Domain’s proprietary IO asset, in a first-in-human Phase I study.
Read MoreAbCellera announced today that it has entered into a multi-year, multi-target strategic collaboration with AbbVie Inc. The partnership will leverage AbCellera’s antibody discovery and development engine to deliver optimized development candidates for up to five targets selected by AbbVie across multiple indications.
Read MoreIMV Inc. today announced positive initial patient data from the VITALIZE Phase 2B trial evaluating its lead DPX product, MVP-S, in combination with pembrolizumab in patients with relapsed, refractory Diffuse Large B Cell Lymphoma (“r/r DLBCL”) who received at least three previous lines of treatment.
Read MoreDefence Therapeutics Inc., a Canadian biopharmaceutical company specialising in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the successful completion of all GLP studies related to its anti-cancer treatment, AccuTOX.
Read MoreDomain Therapeutics, a drug discovery and development company focused on G Protein-Coupled Receptors (GPCRs) in immuno-oncology (IO), today announces the appointments of Professor Antoine Italiano and Professor John Stagg to its Scientific Advisory Board (SAB).
Read MoreMONTREAL (CANADA) – November 29, 2022 – Inversago Pharma Inc. (“Inversago”), a clinical stage biotech company with a unique portfolio of peripherally-acting CB1 inverse agonists, today announced that the first patient has been dosed with INV-202 in a Phase 2 clinical trial in subjects with diabetic kidney disease (DKD).
Read MoreOur executive director, Emmanuelle Toussaint, at BIOQuébec had the honor of participating to the “Rendez-Vous Politique de la Fédération des chambres de commerce du Québec (FCCQ)” with Canada’s Minister of Health, Jean-Yves Duclos
Read MoreQuebec is rich in innovative companies that strive to do things differently to bring our knowledge and skills to another level. We were delighted to honor our members Jenthera Therapeutics, Repare Therapeutics, Ventus Therapeutics, KisoJi Biotechnology, Valence Discovery and Modelis who all innovate in the field of life sciences for the development of new therapies.
Read MoreLAVAL, Québec, May 18, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) announced today that the top line results of its pharmacokinetic (PK) bridging study with IV GTX-104, the Company’s lead drug candidate for the treatment of Subarachnoid Hemorrhage (SAH), met all its planned study endpoints. The primary objective of the study was to evaluate the relative bioavailability of IV GTX-104 compared to oral nimodipine in healthy adult male and female subjects, while the secondary objective was to assess its safety and tolerability. The Company plans to submit these results to the US Food and Drug Administration (FDA), along with its proposed study design for the Phase 3 safety study which is on track to start in the second half of 2022. The safety study is expected to be the final step required to seek regulatory approval under the 505(b)(2) regulatory pathway before submitting a New Drug Application to the FDA.
Read MoreBIOQuébec commissioned The JBL Group to produce a comprehensive account of the situation by first, rigorously documenting the Quebec healthcare system’s recommendation process for Quebec-based innovations and secondly, to develop, with industry partners, public policy proposals that would support the Quebec biopharmaceutical industry’s innovations and development. BIOQuébec’s review was prompted by a widespread perception among many members that Quebec-based drugs and biopharmaceutical industry products were unfavourably considered by the Quebec health and social services network.
Read MoreBIOQuébec is proud to be organizing, in partnership with Investissement Québec International, the Quebec CROs mission during MassBio’s State of Possible Conference, being held from May 4 to 6.
Read MoreGE Healthcare will incorporate Imeka's neuroimaging technology into BrainWave MRI to provide additional insights into central nervous system diseases and disorders
Read MoreBromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreBromont (Québec), April 21 2022 — BIOQuébec is pleased to be releasing the results of a study on the integration of Quebec innovations into our healthcare system. It is also suggests courses of action to better support Quebec-based biopharmaceutical innovations during the entire process and strengthen Quebec’s autonomy.
Read MoreBy June, GIPTIS will invite 10-12 companies to be part of its new public-private health organization and cooperation model in France.
Read More
